PSI is a non-profit organisation formed in 1977 which provides a forum for regular discussion of statistics and issues relating to the practice of statistics in the pharmaceutical industry, as well as promoting good statistical practice within the industry.

Why join PSI

We provide...

opportunities for our members to network, develop themselves and shape the industry

We are...

run by our membership through a network of committees and special interest groups

We promote...

best statistical practice to our members and promote the value of statistics to the external world

Statisticians in the Pharmaceutical Industry
Executive Office: Durford Mill, Petersfield, Hampshire, GU31 5AZ e: t: +44 (0) 845 1800 349

Latest News

  • Drug Development beyond the FDA/EMA – Opportunities and Challenges in Asia Pacific Development Pathways

    Clinical drug development has often had a heavy focus on the needs of the FDA and EMEA. This webinar aims to focus on the needs of the China FDA (cFDA) and Japan’s Pharmaceutical and Medical Device Agency (PMDA) providing both insights into the regulatory requirements, real life examples of local development plans and key things to consider when looking to include these countries in multi-regional trials.
  • 2015 ASA Biopharmaceutical Section FDA-Industry Statistics Workshop

    The ASA Biopharmaceutical Section FDA-Industry Statistics Workshop is sponsored by the ASA Biopharmaceutical Section in cooperation with the FDA Statistical Association. Each year, approximately 800 regulatory, academia and industry colleagues gather together to share insights into key trends in statistical topics relevant to pharmaceutical and medical device development. The 2015 Workshop takes place September 16-18 in Washington D.C. at the Marriott Wardman Park. The plenary includes presentations and panel discussion on The Future of Precision Medicine. As part of the plenary program, Susan A. Murphy, Professor of Statistics and Professor of Psychiatry at the University of Michigan, will discuss the use of mobile devices in micro-randomized trials. Panel discussion will address prepared and audience questions and includes Murphy, Greg Campbell (CDRH/FDA), Cong Chen (Merck), Lisa LaVange (CDER/FDA), Estelle Russek-Cohen (CBER/FDA), and Richard Simon (National Cancer Institute).
Show all news